Costs Help Merck and Novartis, Hit Lilly
NEW YORK (Reuters) - Tight cost controls helped Merck & Co
<MRK.N> and Swiss drugmaker Novartis AG <NOVN.VX> to
better-than-expected quarterly earnings on Monday, while high
expenses contributed to disappointing results from Eli Lilly
and Co <LLY.N>.